Irinotecan

Generic Name
Irinotecan
Brand Names
Camptosar, Onivyde, Onivyde pegylated liposomal (previously known as Onivyde)
Drug Type
Small Molecule
Chemical Formula
C33H38N4O6
CAS Number
97682-44-5
Unique Ingredient Identifier
7673326042
Background

Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cell death. It is a derivative of camptothecin. Irinotecan was approved for the treatment of advanced pancreatic cancer in October, 2015 (irinotecan liposome injection, trade name Onivyde).

Indication

For the treatment of metastatic colorectal cancer (first-line therapy when administered with 5-fluorouracil and leucovorin). Also used in combination with cisplatin for the treatment of extensive small cell lung cancer. Irinotecan is currently under investigation for the treatment of metastatic or recurrent cervical cancer. Also used in combination with fluorouracil and leucovorin for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy.

Associated Conditions
Esophageal Cancer, Ewing's Sarcoma, Gastric Cancer, High Grade Glioma: Glioblastoma (GBM), Metastatic Cervical Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, Rhabdomyosarcomas, Small Cell Lung Cancer (SCLC), Stage IV Colorectal Cancer, Recurrent, metastatic Colorectal carcinoma, Refractory, metastatic Pancreatic adenocarcinoma
Associated Therapies
-
Clinical Trials
Related News

Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer

First Posted Date
2005-07-11
Last Posted Date
2014-06-17
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
72
Registration Number
NCT00118235
Locations
🇺🇸

Cancer and Leukemia Group B, Chicago, Illinois, United States

🇺🇸

Rhode Island Hospital, Providence, Rhode Island, United States

Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

First Posted Date
2005-06-03
Last Posted Date
2021-03-08
Lead Sponsor
UNICANCER
Target Recruit Count
342
Registration Number
NCT00112658
Locations
🇫🇷

Hopitaux Civils de Colmar, Colmar, France

🇫🇷

Clinique Saint Vincent, Epernay, France

🇫🇷

Centre Hospitalier General, Belfort, France

and more 51 locations

Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors

First Posted Date
2005-06-03
Last Posted Date
2014-01-13
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
36
Registration Number
NCT00112892
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer

First Posted Date
2005-05-26
Last Posted Date
2013-12-12
Lead Sponsor
Amgen
Target Recruit Count
43
Registration Number
NCT00111761

S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer

First Posted Date
2005-05-04
Last Posted Date
2015-11-18
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
22
Registration Number
NCT00109850
Locations
🇺🇸

Christine LaGuardia Phillips Cancer Center at Wellmont Holston Valley Medical Center, Kingsport, Tennessee, United States

🇺🇸

Augusta Oncology Associates - Walton Way, Augusta, Georgia, United States

🇺🇸

Mobile Infirmary Medical Center, Mobile, Alabama, United States

and more 128 locations

Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer

Phase 2
Terminated
Conditions
Cervical Cancer
First Posted Date
2005-03-22
Last Posted Date
2007-04-18
Lead Sponsor
Women and Infants Hospital of Rhode Island
Target Recruit Count
38
Registration Number
NCT00106262
Locations
🇺🇸

Women & Infants' Hospital, Providence, Rhode Island, United States

Irinotecan and Carboplatin in Treating Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer

Phase 2
Completed
Conditions
Lung Cancer
First Posted Date
2005-03-04
Last Posted Date
2013-05-30
Lead Sponsor
Japan Multinational Trial Organization
Target Recruit Count
55
Registration Number
NCT00104793
Locations
🇯🇵

National Hospital Organization - Medical Center of Kure, Hiroshima, Japan

🇯🇵

Tokyo Medical and Dental University, Tokyo, Japan

🇯🇵

Fujisawa City Hospital, Fujisawa, Kanagawa, Japan

and more 8 locations

Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

First Posted Date
2005-02-08
Last Posted Date
2014-05-23
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
71
Registration Number
NCT00103259
Locations
🇺🇸

Eastern Cooperative Oncology Group, Boston, Massachusetts, United States

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

First Posted Date
2005-01-10
Last Posted Date
2013-06-05
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
24
Registration Number
NCT00101270
Locations
🇺🇸

COG Phase I Consortium, Arcadia, California, United States

Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer

Phase 2
Terminated
Conditions
Head and Neck Cancer
Interventions
Drug: irinotecan hydrochloride
First Posted Date
2005-01-07
Last Posted Date
2018-12-06
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
6
Registration Number
NCT00100828
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

🇺🇸

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy